Catalyst Biosciences closes $115M common stock offering

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Commercial Banking: June 22nd Edition

Understanding Loss Given Default A Review of Three Approaches

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy

Catalyst Biosciences Inc. closed its underwritten public offering of 3,382,352 common shares at $34 apiece with gross proceeds of about $115 million.

The shares include the full exercise of the underwriters' option to buy an additional 441,176 shares.

JonesTrading Institutional Services LLC acted as sole book-running manager and Ladenburg Thalmann & Co. Inc. acted as joint book runner.

LifeSci Capital LLC acted as lead manager and B. Riley FBR Inc. acted as co-manager of the offering.